To finally prove the impact of an altered TGF by SGLT2 blockade on CKD outcome parameters, the investigation of the effects of the SGLT2 blocker in animal models without a TGF such as adenosine-1 receptor knockout mice would be helpful. The gene discussed is SLC5A2; the disease is chronic kidney disease.